[Boceprevir-benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with Â§ 35a SGB V (dosage evaluation)].
Axel
A
Dignass
Siegbert
S
Faiss
Peter
P
Galle
Peter
P
Layer
Markus
M
Lerch
Peter
P
Malfertheiner
Till
T
Wehrmann
Stefan
S
Zeuzem
D000998:Antiviral Agents / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005762:Gastroenterology / Q000592:standards*; D005858:Germany / Q000453:epidemiology; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods*; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011392:Proline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D000998:Antiviral Agents; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline